CD274 and lung carcinoma: In the wake of these intriguing findings, an exponential number of studies have profiled TME genes on lung cancers by identifying highly specific and accurate signatures capable of predicting molecular subtypes more sensitive to anti-PD-L1/PD1-based therapies (94–97).